SUPPRESSION OF THE IMMUNE-RESPONSE BY A SOLUBLE COMPLEMENT RECEPTOR OF LYMPHOCYTES-B

被引:231
作者
HEBELL, T
AHEARN, JM
FEARON, DT
机构
[1] JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA
[2] JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA
关键词
D O I
10.1126/science.1718035
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The CD19-CR2 complex of B lymphocytes contains proteins that participate in two host-defense systems, the immune and complement systems. The ligand for the subunit of the immune system, CD19, is not known, but the complement receptor subunit, CR2 (CD21), binds activation fragments of the C3 component of the complement system and may mediate immunopotentiating effects of complement. A recombinant, soluble CR2 was prepared by fusing the C3-binding region of the receptor to immunoglobulin G1 (IgG1). The (CR2)2-IgG1 chimera competed with cellular CR2 for C3 binding and suppressed the antibody response to a T cell-dependent antigen when administered to mice at the time of immunization. This inhibitory effect of (CR2)2-IgG1 demonstrates the B cell-activating function of the CD19-CR2 complex and suggests a new method for humoral immunosuppression.
引用
收藏
页码:102 / 105
页数:4
相关论文
共 30 条
[1]   STRUCTURE AND FUNCTION OF THE COMPLEMENT RECEPTORS, CR-1 (CD35) AND CR-2 (CD21) [J].
AHEARN, JM ;
FEARON, DT .
ADVANCES IN IMMUNOLOGY, 1989, 46 :183-219
[2]   CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE [J].
ARUFFO, A ;
STAMENKOVIC, I ;
MELNICK, M ;
UNDERHILL, CB ;
SEED, B .
CELL, 1990, 61 (07) :1303-1313
[3]   MUTATIONAL ANALYSIS OF THE IMMUNOGLOBULIN HEAVY-CHAIN PROMOTER REGION [J].
BALLARD, DW ;
BOTHWELL, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (24) :9626-9630
[4]   THE REGULATION OF IGG SUBCLASS PRODUCTION IN MAN - LOW SERUM IGG4 IN INHERITED DEFICIENCIES OF THE CLASSICAL PATHWAY OF C-3 ACTIVATION [J].
BIRD, P ;
LACHMANN, PJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (08) :1217-1222
[5]  
BOTTGER EC, 1985, J IMMUNOL, V135, P4100
[6]   COMPARISON OF THE EFFECTOR FUNCTIONS OF HUMAN-IMMUNOGLOBULINS USING A MATCHED SET OF CHIMERIC ANTIBODIES [J].
BRUGGEMANN, M ;
WILLIAMS, GT ;
BINDON, CI ;
CLARK, MR ;
WALKER, MR ;
JEFFERIS, R ;
WALDMANN, H ;
NEUBERGER, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) :1351-1361
[7]   DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY [J].
CAPON, DJ ;
CHAMOW, SM ;
MORDENTI, J ;
MARSTERS, SA ;
GREGORY, T ;
MITSUYA, H ;
BYRN, RA ;
LUCAS, C ;
WURM, FM ;
GROOPMAN, JE ;
BRODER, S ;
SMITH, DH .
NATURE, 1989, 337 (6207) :525-531
[8]  
CAREL JC, 1990, J BIOL CHEM, V265, P12293
[9]  
CARTER R, UNPUB
[10]  
CARTER RH, 1989, J IMMUNOL, V143, P1755